XML 52 R13.htm IDEA: XBRL DOCUMENT
v3.20.1

Intangible Assets and Goodwill | 3 Months Ended
--- | ---
Mar. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract] |
Intangible Assets and Goodwill | Intangible Assets and Goodwill Intangible Assets Intangible assets, net of accumulated amortization, impairment charges and adjustments, are summarized as follows:
|  |  | As of March 31, 2020 |  | As of December 31, 2019
(In millions) | Estimated Life |  | Cost |  | Accumulated Amortization |  | Net |  | Cost |  | Accumulated Amortization |  | Net
Completed technology | 4-28 years |  | $ | 7,379.3 |  |  | $ | (4,952.9 | ) |  | $ | 2,426.4 |  |  | $ | 7,379.3 |  |  | $ | (4,881.4 | ) |  | $ | 2,497.9 |
In-process research and development | Indefinite until commercialization |  | 956.5 |  |  | — |  |  | 956.5 |  |  | 965.5 |  |  | — |  |  | 965.5 |
Trademarks and trade names | Indefinite |  | 64.0 |  |  | — |  |  | 64.0 |  |  | 64.0 |  |  | — |  |  | 64.0 |
Total intangible assets |  |  | $ | 8,399.8 |  |  | $ | (4,952.9 | ) |  | $ | 3,446.9 |  |  | $ | 8,408.8 |  |  | $ | (4,881.4 | ) |  | $ | 3,527.4 |
For the three months ended March 31, 2020, amortization and impairment of acquired intangible assets totaled $71.5 million as compared to $68.2 million in the prior year comparative period. For the three months ended March 31, 2020 and 2019, we had no impairment charges. Completed Technology Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI from Elan Pharma International Ltd., an affiliate of Elan Corporation plc. The net book value of the TYSABRI asset as of March 31, 2020, was $1.8 billion. Completed technology also includes $154.6 million in milestone payments made to Alkermes Pharma Ireland Limited, a subsidiary of Alkermes plc, following the approval of VUMERITY in the U.S. in October 2019, net of accumulated amortization. IPR&D Related to Business Combinations IPR&D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&D assets as of March 31, 2020, relates to the various IPR&D programs we acquired in connection with our acquisitions of NST, Convergence Pharmaceuticals Holdings Ltd. (Convergence) and Biogen International Neuroscience GmbH (BIN). The majority of the balance relates to our acquisition of NST in June 2019 whereby we acquired IPR&D programs with an estimated fair value of $700.0 million. For additional information on our acquisition of NST, please read Note 2, Acquisitions, to these condensed consolidated financial statements. Vixotrigine During the third quarter of 2018 we completed a Phase 2b study of vixotrigine for the potential treatment of painful lumbosacral radiculopathy (PLSR). The study did not meet its primary or secondary efficacy endpoints and we discontinued development of vixotrigine for the potential treatment of PLSR. In addition, we delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of trigeminal neuralgia (TGN) as we awaited the outcome of ongoing interactions with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies, a more detailed review of the data from the Phase 2b study of vixotrigine for the potential treatment of PLSR and insights from the Phase 2 study of vixotrigine for the potential treatment of small fiber neuropathy. The TGN program has experienced numerous delays in development in the periods since we acquired the program and the fair value of this asset is not significantly in excess of carrying value. In addition, we are currently testing vixotrigine in another mid-stage clinical trial, in a different neuropathic pain indication, for which we also have an IPR&D asset. Data from that trial is expected in mid-2020. This data may affect the economic value of vixotrigine and the IPR&D assets for one or both programs could be impaired if assumptions used in determining their fair value change. As of March 31, 2020, the carrying value associated with our vixotrigine IPR&D assets was $161.7 million. Estimated Future Amortization of Intangible Assets Our most recent long-range planning cycle was completed in the second quarter of 2019. Based upon this most recent analysis, the estimated future amortization of acquired intangible assets for the next five years is expected to be as follows:
(In millions) |  | As of March 31, 2020
2020 (remaining nine months) |  | $ | 193.0 |
2021 |  | 220.0 |
2022 |  | 220.0 |
2023 |  | 230.0 |
2024 |  | 230.0 |
2025 |  | 220.0 |
Goodwill The following table provides a roll forward of the changes in our goodwill balance:
(In millions) |  | As of March 31, 2020
Goodwill, beginning of period |  | $ | 5,757.8 |
Other |  | (5.8 | )
Goodwill, end of period |  | $ | 5,752.0 |
As of March 31, 2020, we had no accumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for goodwill and intangible assets. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration